Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples